Search Results
Your search for ,ASh matches 1521 pages
Showing 1201 - 1250BELA Trial Reborn: Bosutinib Produces Improved Results in Chronic Myeloid Leukemia
The initial reports of the BELA trial (Bosutinib Efficacy and safety in chronic myeloid LeukemiA), presented at ASH 2010, were deflating. At 12-month follow-up, bosutinib failed to meet BELA’s primary endpoint. Things have since turned around, however, and results from the 24-month analysis...
Expert Point of View: Post-CHOP Radioimmunotherapy Comparable to Rituximab Given along with CHOP in Previously Untreated Follicular Lymphoma
SWOG S0016, which compared treatment with CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, plus rituximab [Rituxan]) and CHOP-RIT (CHOP plus tositumomab/iodine-131 tositumomab [Bexxar]) in patients with follicular lymphoma, was one of the most important studies at the 2011 ASH...
2012 Oncology Meetings
MARCH ACR 5th Annual PET/CT SymposiumMarch 1-4 • Stowe, Vermont For more information: www.acr.org 3rd Asian Breast Cancer CongressMarch 3-4 • Bangalore, India For more information: http://abcconline.net TAT 2012 (International Congress on Targeted AntiCancer Therapies)March 8-10 • Amsterdam, The...
Carfilzomib May Offer Advantages in Patients with Relapsed/Refractory Multiple Myeloma
Carfilzomib is an oral second-generation proteasome inhibitor with a mechanism of action that may increase efficacy and reduce adverse effects currently associated with proteasome inhibitor therapy. It is being investigated for use in multiple myeloma and select solid tumors, and the FDA has...
Expert Point of View: Peripheral Blood or Bone Marrow as Unrelated Donor Stem Cell Source
This large randomized, controlled trial took a lot of time and extensive resources, and yet survival was the same between the two types of unrelated donor transplant sources, noted Stephanie J. Lee, MD, Professor of Medicine at Washington University and the Fred Hutchinson Cancer Center in Seattle. ...
Expert Point of View: Long-term Survival Benefit and Safety Confirmed for VMP Regimen in Multiple Myeloma in Patients Who Were Not Transplant Candidates
Commenting on the 5-year follow-up data of VISTA presented at the 2011 ASH meeting, Kenneth C. Anderson, MD, said, “This is the longest follow-up of protocols incorporating novel therapies into initial therapy of nontransplant candidates in myeloma. Remarkably, bortezomib with melphalan and...
Long-term Survival Benefit and Safety Confirmed for VMP Regimen in Multiple Myeloma in Patients Who Were Not Transplant Candidates
Five-year analysis of the VISTA trial confirms a survival advantage with VMP (bortezomib [Velcade], melphalan, and prednisone) for upfront treatment of multiple myeloma in patients who were not transplant candidates. At a median follow-up of 60.1 months, a 13-month improvement in overall survival...
2012 Oncology Meetings
MARCH Hematology/Oncology Pharmacy Association 8th Annual Meeting March 21-24 • Orlando, Florida For more information: www.hoparx.org 65th Society of Surgical Oncology Annual Meeting March 21-24 • Orlando, Florida For more information: www.surgonc.org Society of Interventional Radiology 37th...
ASH 2011 Presentations Include Novel Agents and New Strategies in Leukemia, Lymphoma, and Myeloma
Attendees at the 53rd Annual Meeting of the American Society of Hematology (ASH), held recently in in San Diego, were able to choose from a wide range of interesting and important sessions exploring hematologic malignancies. In addition to The ASCO Post’s regular news coverage from the meeting,...
Maintenance with Lenalidomide or Bortezomib Prolongs Remission in Elderly Patients with Multiple Myeloma
The benefit of maintenance therapy in newly diagnosed multiple myeloma patients ineligible for stem cell transplant, such as the elderly, is still debated, though value appears to be emerging, according to studies presented at the 2011 American Society of Hematology (ASH) Annual Meeting....
2012 Oncology Meetings
APRIL 3rd European Lung Cancer ConferenceApril 18-21 • Geneva, Switzerland For more information: www.esmo.org Diagnosis and Treatment of Advanced Forms of Prostate Cancer, Bladder Cancer and Kidney CancerApril 20-21 • Kiev, Ukraine For more information: http://nbscience.com Organisation for...
2012 Oncology Meetings
MAY AUA Annual MeetingMay 19-23 • Atlanta, Georgia For more information: www.aua2012.org Keystone Symposia: The Role of Inflammation during CarcinogenesisMay 20-25 • Dublin, Ireland For more information: www.keystonesymposia.org JUNE Society for Immunotherapy of Cancer Primer on Tumor Immunology...
2012 Oncology Meetings
JUNE World Conference on Interventional OncologyJune 14-17 • Chicago, Illinois For more information: www.wcio2012.org Emerging Strategies in Treatment of Non-Small Cell Lung Cancer and Head & Neck CancerJune 16 • Atlanta, Georgia For more information: http://cancernetus.com 8th Central European ...
2012 Oncology Meetings
July Pan Pacific Lymphoma ConferenceJuly 17-20 • Lahaina, Maui, Hawaii For more information: unmc.edu/panpacificlymphoma 13th International Lung Cancer CongressJuly 19-22 • Huntington Beach, California For more information: http://cancerlearning.onclive.com 5th Latin American Lung Cancer...
Meetings Calendar
September 1st Multidisciplinary Symposium: Molecular Oncology: From Laboratory Bench to MedicineSeptember 17-22 • Kyiv, Ukraine For more information: http://rmd.org.ua/en Cancer Vaccines: Advances in Design, Therapy and EfficacySeptember 19-20 • London, United Kingdom For more information:...
Which Rituximab-based Regimen Works Best in Non-Hodgkin Lymphoma?
The treatment of non-Hodgkin lymphoma (NHL) patients has been recently informed by several important studies, which were discussed at the Best of ASCO Boston meeting by Michael E. Williams, MD, of the University of Virginia Cancer Center in Charlottesville. Bendamustine Outperforms R-CHOP in NHL...
2012-2013 Oncology Meetings Calendar
October 2012 14th Biennial Meeting of the International Gynecologic Cancer SocietyOctober 13-16 • Vancouver, Canada For more information: www2.kenes.com/igcs2012/Pages/home.aspx 13th World Congress of the International Society for Diseases of the EsophagusOctober 15-17 • Venice, Italy For more...
Developments in Hematologic Cancers Include New Considerations in Treating Challenging Leukemias and Multiple Myelomas
Speakers at the National Comprehensive Cancer Network (NCCN) 7th Annual Congress on Hematologic Malignancies reviewed the current standard of care for various hematologic cancers and explored new concepts in treatment. Below are highlights from presentations on chronic myelogenous leukemia (CML),...
2012-2013 Oncology Meetings
November 2012 AACR-NCI-EORTC Molecular Targets and Cancer TherapeuticsNovember 12-16 • San Francisco, California For more information: www.aacr.org Connective Tissue Oncology Society 17th Annual MeetingNovember 14-17 • Prague, Czech Republic For more information: www.ctos.org Controversies in the...
American Society of Hematology Elects New Leadership
The American Society of Hematology (ASH) recently announced the election of four new members to its Executive Committee, the governing body of the organization, for terms to begin in January 2013. At the same time, ASH President-elect and Vice President will begin their tenures as ASH President and ...
Who Should Receive First-line BEACOPP Therapy for Hodgkin Lymphoma?
At the Pan Pacific Lymphoma Conference, held this year in Maui, Hawaii, Andreas Engert, MD, Chairman of the German Hodgkin Study Group, University Hospital of Cologne, Germany, led off the Hodgkin lymphoma section of the conference with a presentation on optimizing the use of BEACOPP (bleomycin,...
Oncology Meetings
January 2013 3rd International Conference on Medical, Biological and Pharmaceutical SciencesJanuary 4-5 • Bali, Indonesia For more information: www.psrcentre.org Breast-Gynecological International Cancer CongressJanuary 17-18 • Cairo, Egypt For more information: www.bgicc.eg.net/ Highlights of ASH® ...
Updates on Ruxolitinib from ASCO and ASH 2012, including Long-term Survival Data
Ruxolitinib (Jakafi), a novel, oral JAK1 and JAK2 inhibitor, was approved by the FDA on November 16, 2011 for patients with intermediate- or high-risk myelofibrosis. The approval was based on its efficacy in reducing spleen size and improving disease-related burdensome symptoms. In the brief In the ...
American Society of Hematology Launches ASH Foundation
The American Society of Hematology (ASH) has announced the creation of the ASH Foundation dedicated to curing blood diseases. The new foundation will complement and build on the work of the Society by harnessing the generosity of donors to expand the reach of successful ASH programs and develop new ...
Oncology Meetings
January 2013 Breast-Gynecological International Cancer CongressJanuary 17-18 • Cairo, EgyptFor more information: www.bgicc.eg.net/ Highlights of ASH® San Diego, CA and Toronto, CanadaJanuary 18-19 • San Diego, CA and Toronto, Ontario, CanadaFor more information: www.hematology.org/meetings...
Fixed-dose Apixaban Reduces Risk of Recurrent Venous Thromboembolism
Venous thromboembolism is a frequent problem in cancer patients, and approximately 20% of all patients who develop the disease have a recurrence. Extending treatment with two fixed doses of the investigational agent apixaban, a factor Xa inhibitor without laboratory monitoring, may provide a...
Expert Point of View: Martin Dreyling, MD and Joshua Brody, MD
Martin Dreyling, MD, Professor at the University of Munich in Germany, said the most important lymphoma studies presented at the 2012 ASH Annual Meeting focused on ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor. “Basic science has gone mainstream. We will see a revolution during...
Expert Point of View: Claire Dearden, MD
Patients are very excited about this new, well tolerated drug for chronic lymphocytic leukemia (CLL). Ibrutinib is available orally and is not chemotherapy. It produces excellent responses. This is particularly important for elderly [ie, age 65 and older] patients who are not always fit enough to...
Excellent Preliminary Results for Ibrutinib in Chronic Lymphocytic Leukemia
Although still in preliminary testing with no phase III data, ibrutinib is poised to become an important new agent for patients with chronic lymphocytic leukemia (CLL). Two phase II trials reported at the 54th Annual Meeting of the American Society of Hematology (ASH) found that ibrutinib achieved...
Umbilical Cord Blood Transplant: Two Units are No Better Than One in Children with Hematologic Malignancies
Use of two partially HLA-matched units of umbilical cord blood were not superior to a single unit if it contained an adequate number of hematopoietic stem cells, according to a randomized study by the Blood and Marrow Clinical Trials Network. Results were reported at the 54th Annual Meeting of the...
Oral Proteasome Inhibitor May Be a Game-changer in Myeloma
An investigational oral proteasome inhibitor currently known as MLN9708 could make the treatment of multiple myeloma much more convenient and possibly less neurotoxic, according to the results of a phase I/II study of treatment-naive multiple myeloma patients presented at the 54th Annual Meeting of ...
Overall Survival Benefit Achieved with Pomalidomide in Advanced Myeloma
Support for the oral immunomodulatory agent pomalidomide for multiple myeloma took a step forward when the phase III MM-003 trial showed a survival advantage in patients with advanced disease, in addition to a doubling in progression-free survival, when pomalidomide was given with low-dose...
Pivotal Trial Shows Robust Activity of Ponatinib in Some Heavily Pretreated Leukemias
The pivotal phase II Ponatinib Ph+ ALL and CML Evaluation (PACE trial) found that 1 year of treatment with the novel investigational drug ponatinib achieved robust activity in heavily pretreated patients with chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic...
Last-minute ‘Fiscal Cliff’ Deal by Congress Again Averts Medicare Cuts to Physicians
A last-minute patch to the sustainable growth rate formula included in the “fiscal cliff” deal averted massive cuts to oncologists who care for and treat Medicare patients. “This end-of-year crisis management once again demonstrates the critical need for fundamental reform of the Medicare...
Oncology Meetings
February Highlights of ASH® Miami, FL and San Francisco, CAFebruary 1-2 • Miami, Florida, and San Francisco, CaliforniaFor more information: www.hematology.org/meetings Optimizing Outcomes in Colorectal CancerFebruary 7 • Boston, MassachusettsFor more information: www.omedlive.com Interventional...
Expert Point of View: Martin Dreyling, MD
Commenting on the UK NCRI RAPID trial data presented at the ASH Annual Meeting, Martin Dreyling, MD, Professor of Medicine and Head of the Lymphoma Program at the University Hospital Grosshaden, Ludwig Maximilian University, Munich, Germany, stated, “This is a straightforward study suggesting that...
PET-negative Scan after Short-course Chemotherapy Identifies Early Hodgkin Lymphoma Patients Who Can Forgo Radiation
Positron-emission tomography (PET)-directed therapy is promising for early-stage Hodgkin lymphoma, according to results of the UK NCRI RAPID trial presented at the 54th Annual Meeting of the American Society of Hematology (ASH).1 The use of PET scan enabled the identification of a population of...
Inotuzumab Moves Forward in Relapsed/Refractory ALL
Single-agent inotuzumab ozogamicin achieved an encouraging overall response rate of 57% in the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL) in a phase II trial reported at the 54th Annual Meeting of the American Society of Hematology (ASH). Response was independent of monthly ...
Expert Point of View: Martin Dreyling, MD
Martin Dreyling, MD, Professor of Medicine at Ludwig Maximilians University in Munich and Coordinator of the European Mantle Cell Lymphoma Network, commented on the data emerging for ibrutinib in lymphoma. “Ibrutinib is the molecule of the year at ASH,” he told The ASCO Post. “With other molecular ...
SIDEBAR: Ibrutinib in Other Hematologic Tumors
At the 2012 ASH Annual Meeting, researchers also reported preliminary results for ibrutinib in diffuse large B-cell lymphoma, follicular lymphoma, and multiple myeloma. A multicenter phase II study in 70 heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma in two...
Ibrutinib in Mantle Cell Lymphoma Yields 'Unprecedented' Response Rates
The investigational agent ibrutinib demonstrated “unprecedented” single-agent activity in relapsed or refractory mantle cell lymphoma, according to the lead author of an international phase II study reported at the Annual Meeting of the American Society of Hematology (ASH).1 Durable Responses “The...
Expert Point of View: Sagar Lonial, MD
Commenting on Dr. Palumbo’s presentation at the ASH meeting, Sagar Lonial, MD, Professor of Hematology and Medical Oncology at the Winship Cancer Center at Emory University, Atlanta, noted that while a survival benefit has been associated with maintenance lenalidomide (Revlimid) after transplant,...
Survival Benefit Achieved with Four Drugs plus Maintenance in Myeloma
An overall survival benefit in newly diagnosed multiple myeloma was attained with a four-drug induction regimen followed by a duet for maintenance in a study from the Italian GIMEMA network. Antonio Palumbo, MD, Chief of the Myeloma Unit at the University of Torino in Italy, reported the findings...
Oncology Meetings
February Scripps Cancer Center’s 33rd Annual Clinical Hematology and Oncology ConferenceFebruary 16-19 • San Diego, CaliforniaFor more information:www.scripps.org/events/clinical-hematology-and-oncology-february-16-2013 2013 Translational Research Cancer Centers Consortium: The Power of Negative...
ASH International Clinical Collaboration Replicates High Cure Rate of APL in Developing Countries
The work of an American Society of Hematology (ASH) international clinical network collaborative focused on modernizing treatment protocols for patients in the developing world with acute promyeloctyic leukemia (APL) has drastically improved cure rates in patients in Central and South America. In...
ASH Highlights Included New Data in Myeloma, Lymphoma, and Leukemia, plus Studies of Mucositis and Graft-vs-Host Disease
The 54th Annual Meeting of the American Society of Hematology (ASH) featured about 5,000 abstracts, including oral sessions and posters, as well as named lectures and symposia. In addition to our regular news coverage from the meeting, below are capsule summaries of a few news highlights that we...
Daunorubicin-free Induction Therapy for Standard-risk Childhood Acute Lymphoblastic Leukemia
Omitting daunorubicin from induction therapy for children with standard-risk acute B-cell lymphoblastic leukemia (ALL) does not compromise survival and at the same time reduces the risk of associated toxicities, including myelosuppression and cardiac damage, according to results of the large phase...
Expert Point of View: Farhad Ravandi, MD
Over the past 2 decades, we have witnessed remarkable progress in the treatment of patients with acute promyelocytic leukemia (APL). The introduction of all-trans retinoic acid (ATRA) in the front-line therapy setting and arsenic trioxide in the relapse setting had already led to a significant...
Chemotherapy-free Regimen Successful in Acute Promyelocytic Leukemia
For the first time, a chemotherapy-free regimen was superior to conventional cytotoxic chemotherapy for the treatment of acute promyelocytic leukemia (APL). The combination of all-trans retinoic acid (ATRA) plus arsenic trioxide (Trisenox) achieved significantly superior overall survival compared...
We Need Gemtuzumab Available Again to Treat AML
The word “revival” signifies a renewed use or acceptance after a period of inactivity; similarly, the word “resurrection” refers to the concept of an entity coming back to life after death. In the past year, these terms have been used frequently by us (and others) in articles calling for the return ...
